002294.SZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 03:04):

Stats
Today's Volume	4.52M
Average Volume	5.22M
Market Cap	30.70B
EPS	CNY0.0900 ( 2024-03-25 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	54.10
ATR14	CNY0.0280 (0.10%)

Volume Correlation

Long: -0.10 (neutral)

Short: -0.06 (neutral)

Signal:(44.603) Neutral

Shenzhen Salubris Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shenzhen Salubris Correlation - Currency/Commodity

0.03
( neutral )

0.17
( neutral )

0.00
( neutral )

0.04
( neutral )

0.52
( weak )

0.06
( neutral )

Shenzhen Salubris Financials

Annual	2023
Revenue:	CNY3.32B
Gross Profit:	CNY2.19B (66.07 %)
EPS:	CNY0.530

Q4	2023
Revenue:	CNY900.30M
Gross Profit:	CNY608.21M (67.56 %)
EPS:	CNY0.0924

Q3	2023
Revenue:	CNY772.02M
Gross Profit:	CNY510.82M (66.17 %)
EPS:	CNY0.130

Q2	2023
Revenue:	CNY796.77M
Gross Profit:	CNY531.41M (66.69 %)
EPS:	CNY0.120

Financial Reports:

No articles found.

Shenzhen Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.